Sildenafil: an orally active type 5 cyclic GMP-specific phosphodiesterase inhibitor for the treatment of penile erectile dysfunction.

International journal of impotence research

Volumn 8, Issue 2, 1996, Pages 47-52

  Boolell, M ^a   Allen, M J ^a   Ballard, S A ^a   Gepi Attee, S ^a   Muirhead, G J ^a   Naylor, A M ^a   Osterloh, I H ^a   Gingell, C ^a  

^a PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIC GMP; ENZYME INHIBITOR; ISOENZYME; PHOSPHODIESTERASE; PHOSPHODIESTERASE INHIBITOR; PIPERAZINE DERIVATIVE; SILDENAFIL;

ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; ENZYMOLOGY; HUMAN; IMPOTENCE; MALE; METABOLISM; MIDDLE AGED; ORAL DRUG ADMINISTRATION; PENIS; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; CROSS-OVER STUDIES; CYCLIC GMP; DOUBLE-BLIND METHOD; ENZYME INHIBITORS; HUMANS; IMPOTENCE; ISOENZYMES; MALE; MIDDLE AGED; PENIS; PHOSPHODIESTERASE INHIBITORS; PHOSPHORIC DIESTER HYDROLASES; PIPERAZINES; TREATMENT OUTCOME;

EID: 0030154874     PISSN: 09559930     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (0)